L M Dember
Overview
Explore the profile of L M Dember including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Seldin D, Andrea N, Berenbaum I, Berk J, Connors L, Dember L, et al.
Amyloid
. 2011 Aug;
18 Suppl 1:127-9.
PMID: 21838459
No abstract available.
2.
Girnius S, Seldin D, Quillen K, Dember L, Segal A, Sanchorawala V
Bone Marrow Transplant
. 2010 Apr;
46(1):161-2.
PMID: 20383204
No abstract available.
3.
Sanchorawala V, Wright D, Quillen K, Finn K, Dember L, Berk J, et al.
Bone Marrow Transplant
. 2007 Jun;
40(6):557-62.
PMID: 17589534
Clinical outcomes of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) are tightly linked to the achievement of a hematologic complete response (HCR). We conducted...
4.
Weichman K, Dember L, Prokaeva T, Wright D, Quillen K, Rosenzweig M, et al.
Bone Marrow Transplant
. 2006 Jul;
38(5):339-43.
PMID: 16862166
Light chain deposition disease (LCDD) is caused by a clonal plasma cell disorder in which fragments of monoclonal immunoglobulin light chains form non-fibrillary deposits in various tissues resulting in organ...
5.
Sanchorawala V, Wright D, Seldin D, Falk R, Finn K, Dember L, et al.
Bone Marrow Transplant
. 2003 Dec;
33(4):381-8.
PMID: 14676787
A prospective randomized trial was conducted to study the timing of high-dose intravenous melphalan and autologous stem cell transplantation (HDM/SCT) in AL amyloidosis. In all, 100 newly diagnosed patients were...
6.
Sanchorawala V, Wright D, Seldin D, Dember L, Finn K, Falk R, et al.
Bone Marrow Transplant
. 2001 Nov;
28(7):637-42.
PMID: 11704785
Primary or AL amyloidosis results from a plasma cell dyscrasia in which fibrillar light chain protein deposition leads to organ failure and death. Standard treatment for AL amyloidosis has been...
7.
Chicoskie C, Chaoui A, Kuligowska E, Dember L, Tello R
Clin Imaging
. 2001 Aug;
25(2):114-7.
PMID: 11483421
The use of gadolinium-enhanced magnetic resonance (MR) to isolate an infected renal cyst in the setting of autosomal dominant polycystic kidney disease (ADPKD) has not been previously described. A case...
8.
Dember L, Sanchorawala V, Seldin D, Wright D, Lavalley M, Berk J, et al.
Ann Intern Med
. 2001 May;
134(9 Pt 1):746-53.
PMID: 11329232
Background: Dose-intensive intravenous melphalan with autologous blood stem-cell transplantation induces remission of the plasma cell dyscrasia in a substantial proportion of patients with AL amyloidosis. The impact of this treatment...
9.
Casserly L, Reddy S, Dember L
Am J Kidney Dis
. 2000 Aug;
36(2):405-11.
PMID: 10922321
Venous thromboembolic disease is considered an uncommon event in the end-stage renal disease (ESRD) population. We report five cases of venous thromboembolism (VTE) occurring in dialysis patients within a 1-year...
10.
Comenzo R, Sanchorawala V, Fisher C, Akpek G, Farhat M, CERDA S, et al.
Br J Haematol
. 1999 Mar;
104(3):553-9.
PMID: 10086794
AL amyloidosis patients ineligible for dose-intensive melphalan (200 mg/m2) were enrolled on a phase 11 trial to be treated with two cycles of intermediate-dose melphalan (IDM 100 mg/m2) and mobilized...